The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

A trial tested MRI and microultrasonography guided biopsy separately and in combination for the detection of clinically significant prostate cancer.

The presence of residual tumor cells in the trigone and urethra after robot-assisted radical cystectomy (RARC) is associated with a higher tumor stage, positive margins, and cancer recurrence compared ...

Maintaining systolic blood pressure consistently below 130 mmHg could help decrease the risk for new-onset diabetes in the ...

The Senate has confirmed Dr Jay Bhattacharya as the new director of the NIH and Dr Marty Makary as the new commissioner of the FDA.

The incidence of urinary tract infections after radical cystectomy differs according to how much time elapsed from discharge, with patients who experience UTIs 31-90 days post-discharge at higher ...

In a study of 1134 patients with 4-7 cm renal masses, overall survival did not differ among groups receiving initial active surveillance vs immediate treatment. Active surveillance may be a ...

Cretostimogene is an oncolytic immunotherapy with dual mechanism of action: viral replication leading to tumor lysis and release of granulocyte-macrophage colony stimulating factor.

Although the role of radiation therapy is well established in this setting, the role of radical prostatectomy in treating men with de novo oligometastatic prostate cancer has not been well defined.

More than 2 decades have passed since I became the first full-time editor of Renal & Urology News. During that time, the ...

The FDA expanded the approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and are considered appropriate to ...

The FDA has approved Imfinzi® (durvalumab), in combination with gemcitabine and cisplatin, for the treatment of adult patients with MIBC.